dan 2163 has been researched along with fluvoxamine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Asai, K; Koeda, M; Okubo, Y; Suhara, T; Takahashi, H; Takano, A; Yahata, N | 1 |
| Mendhekar, DN | 1 |
1 trial(s) available for dan 2163 and fluvoxamine
| Article | Year |
|---|---|
Effects of dopaminergic and serotonergic manipulation on emotional processing: a pharmacological fMRI study.
Topics: Adult; Amisulpride; Amygdala; Brain; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Emotions; Fluvoxamine; Hemodynamics; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Positron-Emission Tomography; Selective Serotonin Reuptake Inhibitors; Serotonin Agents; Single-Blind Method; Sulpiride | 2005 |
2 other study(ies) available for dan 2163 and fluvoxamine
| Article | Year |
|---|---|
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Hyperpigmentation with amisulpride.
Topics: Adult; Amisulpride; Antipsychotic Agents; Chronic Disease; Drug Therapy, Combination; Female; Fluvoxamine; Humans; Hyperpigmentation; Obsessive-Compulsive Disorder; Photosensitivity Disorders; Selective Serotonin Reuptake Inhibitors; Sertraline; Sulpiride | 2009 |